share_log

Pharmaniaga's Regularisation Plan Receives Bursa Approval

Pharmaniaga's Regularisation Plan Receives Bursa Approval

Pharmaniaga的常规化计划获得了证交所的批准
Business Today ·  11/29 23:11
big

Pharmaniaga Berhad announced that Bursa Malaysia has approved the Group's Regularisation Plan which will see the group looking towards its financial recovery.

Pharmaniaga Berhad宣布,马来西亚证券交易所已批准该集团的正规化计划,该计划将使该集团着眼于财务复苏。

Pharmaniaga Managing Director, Zulkilfli Jafar said, "The approval from Bursa Malaysia paves the way for Pharmaniaga to implement its comprehensive RP, designed to strengthen the Group's financial position, enhance operational efficiencies, and secure long-term growth."

Pharmaniaga董事总经理Zulkilfli Jafar表示:“马来西亚证券交易所的批准为Pharmaniaga实施其全面的RP铺平了道路,旨在加强集团的财务状况,提高运营效率并确保长期增长。”

"With this latest development, we are now fully focused on executing the RP and achieving a swift exit from PN17," he said.

他说:“随着这一最新进展,我们现在全神贯注于执行RP并迅速退出PN17。”

The RP outlines strategic initiatives aimed at financial restructuring, business optimisation and strengthening Pharmaniaga's core operations. It represents a proactive approach that will initiate rights issuance to provide the Group's shareholders with an opportunity to reinforce their investments; private placement exercise aimed at drawing potential strategic investors to contribute to the Group's value enhancement and growth in the healthcare sector; and a capital reduction process to adjust the Group's share capital.

RP概述了旨在财务重组、业务优化和加强Pharmaniaga核心业务的战略举措。它代表了一种积极的方针,将启动供股,为集团股东提供加强投资的机会;私募活动旨在吸引潜在的战略投资者为集团的价值提升和医疗保健领域的增长做出贡献;以及调整集团股本的资本削减程序。

Zulkifli further added, "The Group assures its stakeholders, including customers, investors, and business partners, that we remain committed to maintaining the highest standards of service and product quality throughout this period of transformation."

Zulkifli进一步补充说:“集团向包括客户、投资者和业务合作伙伴在内的利益相关者保证,在这段转型期间,我们将继续致力于保持最高的服务和产品质量标准。”

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发